// App-Quantinova.ai

443 : Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis

Researchers

Presenter

  • Aurélien Chepy

Principal Investigators

  • Hélène Béhal

  • Alexandre Karras

  • Xavier Puéchal

  • Benjamin Terrier

  • David Jayne

  • Thomas Quéméneur

  • Mary-Jane Guerry

Medical Centers

  • CHU de lille, CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France, Lille, France

  • Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, France

  • HEGP, Paris, France

  • National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France

  • University of Cambridge, Cambridge, United Kingdom

  • Valenciennes Hospital, Valenciennes, France

  • Department of Nephrology, Centre Hospitalier de Valenciennes, Valenciennes., Valenciennes, France

Locations

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Genetic Disorder

  • Infectious Diseases (ID)

  • Nephrology

  • Urology

Disease

  • Anti-neutrophil cytoplasmic antibody-associated vasculitis

  • Glomerulonephritis

Biomarkers

  • N/A

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Oraprine

  • Methotrexate

  • Minocycline

Outcome

  • N/A

Study Design

  • Randomized

  • Prospective

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved